Dowsett M - Search Results

1

Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.

Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, O'Leary B, Herrera-Abreu MT, Cutts RJ, Garcia-Murillas I, Bye H, Walker BA, Gonzalez De Castro D, Yuan L, Jamal S, Hubank M, Lopez-Knowles E, Schuster EF, Dowsett M, Osin P, Nerurkar A, Parton M, Okines AFC, Johnston SRD, Ring A, Turner NC. Pearson A, et al. Among authors: dowsett m. Clin Cancer Res. 2020 Feb 1;26(3):608-622. doi: 10.1158/1078-0432.CCR-18-4044. Epub 2019 Oct 7. Clin Cancer Res. 2020. PMID: 31591187

2

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.

Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Chan CM, et al. Among authors: dowsett m. J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):333-41. doi: 10.1016/s0960-0760(02)00074-2. J Steroid Biochem Mol Biol. 2002. PMID: 12361723

3

Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.

Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Come SE, et al. Among authors: dowsett m. Clin Cancer Res. 2003 Jan;9(1 Pt 2):443S-6S. Clin Cancer Res. 2003. PMID: 12538498 Review. No abstract available.

4

Preoperative models to evaluate endocrine strategies for breast cancer.

Dowsett M. Dowsett M. Clin Cancer Res. 2003 Jan;9(1 Pt 2):502S-10S. Clin Cancer Res. 2003. PMID: 12538507 Review.

5

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Johnston SR, et al. Among authors: dowsett m. Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Clin Cancer Res. 2003. PMID: 12538510 Review.

6

Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications.

Ring A, Dowsett M. Ring A, et al. Among authors: dowsett m. Clin Breast Cancer. 2003 Apr;4 Suppl 1:S34-41. doi: 10.3816/cbc.2003.s.013. Clin Breast Cancer. 2003. PMID: 12756077 Review.

7

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Martin LA, et al. Among authors: dowsett m. J Biol Chem. 2003 Aug 15;278(33):30458-68. doi: 10.1074/jbc.M305226200. Epub 2003 May 29. J Biol Chem. 2003. PMID: 12775708 Free article.

8

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A. Johnston SR, et al. Among authors: dowsett m. J Clin Oncol. 2003 Jul 1;21(13):2492-9. doi: 10.1200/JCO.2003.10.064. J Clin Oncol. 2003. PMID: 12829668 Clinical Trial.

9

Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells.

Zabaglo L, Ormerod MG, Parton M, Ring A, Smith IE, Dowsett M. Zabaglo L, et al. Among authors: dowsett m. Cytometry A. 2003 Oct;55(2):102-8. doi: 10.1002/cyto.a.10071. Cytometry A. 2003. PMID: 14505315 Free article.

10

Circulating tumour cells in breast cancer.

Ring A, Smith IE, Dowsett M. Ring A, et al. Among authors: dowsett m. Lancet Oncol. 2004 Feb;5(2):79-88. doi: 10.1016/S1470-2045(04)01381-6. Lancet Oncol. 2004. PMID: 14761811 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

740 results

Search Page

Filters